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Innovative and new approaches to laboratory diagnosis of Zika and dengue: a meeting report 
 
Running Title: Innovative diagnostic approaches for flaviviruses 
Brief summary: Novel diagnostic approaches for Zika and dengue are on the rise but may not make it 
to the market due to bottlenecks in access to samples for valida.  An international reference 
laboratory response is needed to address these challenges which include networks of in-country 
laboratories, with well-characterized samples to facilitate assay validation and ensure quality 
control. 
 
Adriana Goncalves
1
, Rosanna W. Peeling
1
, May C. Chu
2
, Duane J. Gubler
3
, Aravinda M. de Silva
4
, Eva Harris
5
, 
Maurine Murtagh
6
, Arlene Chua
7
, William Rodriguez
8
, Cassandra Kelly
8
, Annelies Wilder-Smith
9.10, 11‡ 
 
1
 London School of Hygiene & Tropical Medicine, London, UK 
2
 Department of Epidemiology, Colorado School of Public Health, University of Colorado, Anschutz Medical 
Center, Aurora, Colorado, USA 
3
 Emerging Infectious Diseases Program, Duke-NUS Medical School, Singapore 
4
 Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, 
NC, USA 
5
 Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, 
Berkeley, CA, USA 
6
 The Murtagh Group, LLC 
7 
World Health Organization, Geneva, Switzerland
 
8 
Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland
 
9  
Institute of Public Health, University of Heidelberg, Germany 
10
Lee Kong Chian School of Medicine, Singapore 
11
 Department of Global Health and Epidemiology, University of Umea, Umea, Sweden 
 
‡ Corresponding Author: Annelies Wilder-Smith.  
Email: anneliesws@gmail.com 
 
Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jix678/4774529
by London School of Hygiene & Tropical Medicine user
on 03 January 2018
Ac
ce
pte
d M
an
us
cri
pt
 
2 
 
ABSTRACT 
Epidemics of dengue, Zika, and other arboviral diseases are increasing in frequency and severity. 
Current efforts to rapidly identify and manage these epidemics are limited by the short diagnostic 
window in acute infection, the extensive serologic cross-reactivity among flaviviruses, and the lack of 
point-of-care diagnostics to detect these viral species in primary care settings. The Partnership for 
Dengue Control organized a workshop to review the current landscape of Flavivirus diagnostics, 
identified current gaps, and developed strategies to accelerate the adoption of promising novel 
technologies into national programmes. The rate-limiting step to bringing new diagnostics tools to 
the market is access to reference materials and well-characterized clinical samples to facilitate 
performance evaluation. We suggest the creation of an international laboratory response 
consortium for flaviviruses with a de-centralized biobank of well-charachterized samples to facilitate 
assay validation. Access to proficiency panels are needed to ensure quality control, in additional to 
in-country capacity building. 
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Background 
Zika virus (ZIKV) and the dengue viruses (DENV) are arthropod-borne viruses (arboviruses) of the 
Flaviviridae family that co-circulate in tropics and subtropics, along with other arboviruses that share 
the same Aedes spp. mosquito vectors [1]. Several factors including viral evolution, re-distribution of 
vectors, ineffective vector control strategies, population growth, urbanization, and globallzation 
have contributed to the global spread of DENV, ZIKV and other arboviruses [2].  
 
Up to 400 million DENV infections are estimated to occur every year [3], and infection with any of 
the four DENV serotypes (DENV1-4) can cause severe and sometimes fatal disease. The geographical 
expansion of dengue is increasingly associated with more severe disease outcomes [2, 4]. ZIKV is 
following the global spread of DENV [2]. ZIKV infections were first thought to only cause sporadic 
and mild disease in parts of Africa and Asia [5]. A major Zika outbreak with a high attack rate 
occurred for the first time in 2007. During a subsequent outbreak in the Pacific (French Polynesia) in 
2013, ZIKV was linked to severe neurological disease in humans [6]. The recent explosive outbreak in 
the Americas unmasked the association between prenatal ZIKV infections and severe birth defects 
defects [2, 6]. 
  
No specific therapeutic options exist for DENV or ZIKV infections. For DENV, a vaccine was recently 
licensed but has not yet been implemented widely in any of the affected countries[7]; for ZIKV, at 
least 45 vaccine candidates are now in development but a licensed vaccine will not be available for 
years to come[8]. There is an urgent need for highly specific diagnostic assays that can identify and 
discriminate between co-circulating DENV and ZIKV for efficient case management, surveillance, 
control, and vaccine trials. In May 2017, the Partnership for Dengue Control (PDC)[9] organised a 
workshop with approximately 80 key stakeholders and thought leaders to address critical issues 
related to the diagnosis and surveillance of ZIKV and DENV. The workshop was organised around 
three questions:  
i) What is the status of Zika and dengue diagnostics?  
ii) What technological innovations might be available in the near, intermediate and long-
term future?  
iii) What is needed to make these technologies readily available where they are most 
needed? 
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The following is a summary of key outcomes that emerged from the meeting. 
 
What is the status of Zika and dengue diagnostics? 
Individuals infected with DENV and ZIKV may be asymptomatic or display a similar constellation of 
initial clinical symptoms [10]. Hence, virus-specific assays are required for accurate diagnosis. Since 
the first isolation of DENV during World War II [11, 12], a number of diagnostic methods commonly 
used for viral detection, such as viral isolation, Plaque Reduction Neutralization Test (PRNT), the IgM 
Enzyme-Linked Immunosorbent Assay (ELISA), and, in the 1990s, Reverse Transcription-Polymerase 
Chain Reaction (RT-PCR) [13] were developed for DENV (Figure 1) and other medically relevant 
flaviviruses. 
 
Assays to detect DENV and ZIKV can be divided into two main categories: a) assays to detect the 
pathogen (viral isolation, viral nucleic-acid testing (NAT), or viral antigen detection); and b) assays to 
detect exposure to the pathogen (detection of virus-specific antibodies such as IgM, IgG, and IgA). 
Assay selection depends both on the timing of sample collection and the purpose of testing (Figure 
2). The viremic period of flaviviral infections is transient and short-lived; duration of viral shedding 
and the presence of ZIKV RNA can be variable across sample types (e.g., serum, whole blood, urine, 
saliva, amniotic fluid) [6, 14] and different hosts (e.g., pregnant women, other adults) [15]. A 
negative viral isolation and/or NAT result does not exclude the presence of a current infection.  
 
In the convalescent phase of infection, serologic methods are preferred, though paired acute and 
convalescent samples are required to distinguish current from past infections [16]. The major 
challenge of ZIKV and DENV diagnosis by serology is the extensive cross-reactivity of antibody 
responses resulting from prior flaviviral infections and/or vaccination [17-19]. Figure 3 details the 
applications, advantages, and limitations of the different types of assays available for the detection 
of DENV and ZIKV infections.  
 
Landscape overview and existing gaps 
Both “in-house” assays as well as commercial kits are available to detect ZIKV and DENV infections 
(Figure 4). Most of the available technologies require laboratory facilities with appropriate diagnostic 
competence (Figure 4); point-of-care assays remain limited. Zika commercial kits include NAT and 
serological assays. The current ZIKV NAT assays have not yet gone through much rigorous 
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evaluations[20], and the evidence is even scarcer for serological assays. Antigen detection assays for 
the diagnosis of ZIKV infections are currently not available on the market. 
 
Performance of commercial dengue diagnostics has improved over the last decade. These include 
two FDA approved assays (one RT-PCR and one IgM capture ELISA). Additionally, there are several 
rapid lateral flow assays (RDTs) for the detection of DENV NS1 antigen, DENV-specific IgM 
antibodies, or both (Figure 4), none of which are FDA approved. RDTs hold promise as future point-
of-care (POC) applications; however, the clinical performance of these assays has been highly 
variable [21].  
 
While dengue serological assays have been clinically validated, their specificity has decreased by 
cross-reactivity in the context of the recent co-circulation of ZIKV [22]. In general, to date very few 
dengue and Zika diagnostic assays have been adequately and independently evaluated using clinical 
specimens from both ZIKV-infected and DENV-infected populations,. Diagnostic assays that can 
accurately detect and, distinguish co-circulating flaviviral infections and predict severe disease 
outcomes at or near POC are urgently needed.  
 
What technological innovations might be available in the near, intermediate and long-term 
future? 
Different companies and research groups were invited to present technologies to detect DENV and 
ZIKV.. In the following, we discuss the technologies in the pipeline (Figure 4, in bold) and their 
potential to change the paradigm of flaviviral diagnosis. 
 
Pipeline assays to detect the pathogen  
Nucleic-acid testing (NAT) 
Simpler and faster alternatives to traditional RT-PCR methods have the potential to be used at or 
near POC. These include cartridge-based “sample in, answer out” multiplex real-time RT-PCR assays 
that can simultaneously detect ZIKV, DENV1-4, and also other arboviral infections such as 
chikungunya virus (CHIKV)- an alphavirus- , and other viral infections (3-plex to 6-plex combinations) 
from a single specimen in less than two hours. Arboviral assays are being developed for use on 
existing industry platforms that were previously validated and implemented for other molecular 
tests. This strategy illustrates the utility of “open-platform” systems that can easily incorporate 
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newly-developed molecular amplification methods to suit an emergent medical need, such as ZIKV. 
Another advantage of these systems is the ability to transmit data wirelessly and monitor the results 
remotely. The disadvantage is that these platforms are costly, and some require technical expertise 
and laboratory infrastructure that are not widely available. 
The development of more portable molecular platforms linked to faster isothermal amplification 
methods independent of thermal cycling, such as recombinase polymerase amplification (RPA)[23], 
loop-mediated isothermal amplification (LAMP), and others are also underway for singleplex and 
multiplex detection of ZIKV and other arboviruses. In prototype formats, results can be achieved in 
less than one hour, and assays can potentially be applied to settings without electricity or highly 
trained users. Proof-of-principle studies exist [23-30], but further simplification of sample 
preparation and more robust clinical performance evaluation will be required. Innovative 
technologies, such as clustered regularly interspaced short palindromic repeats (CRISPR)-based RNA 
sensing, robotics, microfluidics, smartphones, and 3D printers are being used to develop these 
assays. Other NAT innovations include the use of paper-based strips for multiplex detection of ZIKV, 
DENV, and CHIKV end-point RT-PCR products [31]. 
 
Antigen detection assays 
High-affinity monoclonal antibodies (Mabs) that recognize specific epitopes on ZIKV antigens are 
required to develop antigen detection assays, and are either in development or were developed for 
NS1[32, 33], including the development of RDTs [34].  
 
Pipeline assays to detect past exposure  
Given our understanding of the cross-reactivity of current antibody detection methods for 
flaviviruses, there is a lack of reliable reference diagnostics against which to compare newly 
developed specific serological assays. Detection of virus-specific neutralizing antibodies by PRNT can 
be useful to discriminate viral species and serotypes in primary infections. However, the specificity 
of PRNT in sequential DENV infections, or sequential DENV and ZIKV infections and at early time-
points post-infection is limited [32, 35, 36]. Interestingly, little cross-neutralization is detected in late 
convalescent samples (>2 months post-infection) after DENV and ZIKV infections [37]. These 
observations highlight the importance of the timing of sample collection and the history of exposure 
to past infections to inform the serodiagnosis of flaviviral infections. It is critical to evaluate multiple 
flaviviruses simultaneously in neutralization assays to interpret the results appropriately. 
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Strongly neutralizing human monoclonal antibodies target quaternary structure epitopes that 
typically bind across envelope (E) proteins displayed on the surface of the viral particles [38-40]. 
Epitopes with high sequence homology among serotypes and viral species can trigger cross-reactive 
(CR) antibody responses, whereas unique epitopes can lead to type-specific (TS) antibody responses. 
This information is being used to rationally design ZIKV and DENV E and NS1 recombinant antigens 
for specific serological assays.  
 
Isolated human ZIKV TS anti-NS1 Mabs were used to identify TS recognition sites on ZIKV NS1 
protein by antibody competition assays [32]. One of these antibodies was adapted to a competition-
based ELISA in which serum antibodies are measured for their ability to block the binding of a ZIKV 
NS1-specific Mab to solid-phase ZIKV NS1 [41]. This approach, named ZIKV NS1 blockade-of-binding 
(BOB) ELISA, was shown to be more specific than traditional ELISA assays. Clinical validation in large 
multicentre cohorts of patients stratified by exposure to DENV and ZIKV infection, immune status 
and timing of sample collection confirmed the high specificity and sensitivity of the assay [41]. The 
ZIKV NS1 BOB ELISA has been implemented in laboratories of six different countries (Brazil, Italy, 
Nicaragua, Switzerland, United Kingdom, and United States).  
 
Nanotechnology-based technologies have also been developed, including simple-to-use readout 
platforms with data connectivity that use disposable microfluidic cartridges for rapid detection of 
ZIKV and DENV antibodies/antigen; and a multiplex serological assay that uses near‐infrared 
fluorescence enhanced (NIR-FE) imaging on a nanoscale plasmonic gold microarray antigen platform 
(12-plex) for antibody detection on two different channels [42]. The latter was shown to detect and 
distinguish IgG antibodies from ZIKV- and DENV-infected patients, as well as determine the timing of 
exposure to infection by measuring IgG avidity..  
 
What is needed to make these technologies field-available? 
For the last 25 years, routine diagnostic approaches have mainly included laboratory-based RT-PCR, 
IgM detection, and PRNT. Recognition of Zika as a public health emergency of international concern 
(PHEIC) has galvanized the development of new diagnostic assays to detect flaviviral infections. 
While these efforts must be encouraged, it is equally important to look downstream and identify the 
issues around translating research into a product that is field-available, robust, easy-to-use, 
reasonably inexpensive, accurate and has demonstrable clinical impact. Previous R&D experience 
has shown that the path from diagnostic development to adoption is long and fragmented [16]. 
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There is a massive attrition from the number of tests that undergo initial development to being 
ultimately adopted for routine use, the so-called “valley of death”.  
 
How can we accelerate the pathway from discovery to adoption?  
The five major steps identified for optimization (Figure 4 A-E) are discussed below and summarized 
in Table 1. 
 
A. Market uncertainty  
For diagnostic countermeasures to be readily available, research and development (R&D) must 
happen before rather than in response to an outbreak [43]. The unpredictable and episodic nature 
of outbreaks brings uncertainty to the market, and diagnostic companies are left unable to 
adequately forecast demand and establish business models that allow a return on investment. Even 
when a product is brought into the market, there is no guarantee that it will be adopted by national 
health authorities. Once a PHEIC has ended, sustained manufacturing support of the product may be 
at stake. Sustainable markets are required to ensure that validated, approved, high-quality 
diagnostics remain available for use in the next outbreak event. As such, innovative financial 
incentives are needed to achieve sustainable emergency preparedness for diagnostics. From 
investments in product development to the establishment of partnerships and the creation of 
models to support scalable adoption into national programmes, a variety of mechanisms have been 
proposed or established to overcome some of the challenges.  
 
The WHO R&D Blueprint for Actions to Prevent Epidemics has initiated a call for open-platform 
technologies to improve R&D preparedness against global health emergencies, so that in the event 
of an epidemic diagnostic kits can be made available in a short time-frame [44]. Furthermore, there 
was a call for a coalition between diagnostic preparedness efforts and programmes that finance and 
manage the development of vaccines [43]. As a result, CEPI∙dx, a new partnering model between the 
Coalition for Epidemic Preparedness Innovations (CEPI), the Foundation for Innovative New 
Diagnostics (FIND) and other diagnostic partners has been created.  
 
B. Target Product Profiles (TPPs) 
TPPs are used to define the desired technical and operational minimum characteristics of diagnostic 
tests to ensure the development of the most impactful products. TPPs are aspirational in nature; 
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however, excessively stringent requirements may deter industry partners from developing new 
products and lead to a lack of diagnostic tests meeting those requirements. Strategies on how to 
best define the desired characteristics of TPPs and/or inform the use of diagnostic tests when those 
requirements are not met have been proposed. For example, a slightly less accurate test might 
provide a higher public health impact in terms of increased access to testing compared to a more 
accurate but expensive or complex test (eg the approach used to approve the use of HIV self-testing 
and malaria RDTs in the past). As such, it is important to consider how the assay will be used, in 
which setting, and for what purpose, eg surveillance, early-warning, clinical management at point of 
care, as different applications will have different technical and operational requirements. A weighted 
risk and benefits approach within different use scenarios may be more appropriate not only to 
define but also to guide regulatory approval and adoption. 
 
C. Assay optimization and clinical validation 
Internationally accepted reference preparations to compare and potentially standardize the 
different assays are crucially important[45]. WHO has established numerous reference preparations, 
most of them as WHO International Standards (WHO IS). For Zika RNA, the biological standard for 
molecular tests was characterized for the majority of NAT based assays available[46], and the 
complete sequence of the Zika virus of this reference preparation was published[47] and established 
as WHO IS. Lack of access to biobanks of well-characterized clinical specimens delays the process of 
test optimization, clinical validation, and product adoption. This lack was identified as the most 
significant bottleneck along the pathway from development to adoption.  
 
Of note, the pathway to adoption of “in-house” assays and of commercial kits differs substantially. 
Quality-assured clinical laboratories can develop, validate, and then implement their “in-house” 
assays. In contrast, commercial diagnostic kits go through regulatory approval processes that may 
require large clinical validation studies, manufacturing under a quality management system, and 
some level of distribution capacity. The different streams of test development make it challenging to 
determine relative comparability of the accuracy of the different tests as very few of them share the 
same calibration controls (i.e., internal positive controls used for measuring the reactivity of a 
diagnostic test) or screening panels (i.e., a small set of coded samples that include high positive, low 
positive, cross-reactive, and negative samples, to measure the specificity and sensitivity of a 
diagnostic test). Obtaining irreplaceable clinical specimens is costly; the same test materials cannot 
be used throughout the development process. Access to clinical samples becomes even more 
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challenging during an outbreak with multiple demands to prioritize assay validation in a short time-
frame and inability to do head-to-head comparisons. 
 
A coordinated network of quality-assured laboratories that are well trained in assay validation and 
performance evaluation could be leveraged a priori. Such an approach would  alleviate pressure on 
the countries involved in outbreak response, yet provide access to clinical samples and data in a way 
that may be acceptable to the different parties. Of note, local restrictions on the export of clinical 
samples (as witnessed during the Zika outbreak) limits sample sharing for product validation outside 
the affected countries [43]. The involvement of a network of capable local laboratories would have 
the advantage to overcome the need for out-of-country sample transfer and facilitate country 
involvement and capacity develpment at an early stage of product development. A transparent and 
fair process of engagement needs to be put into place to minimize distrust and ensure access and 
equitable sharing of specimens and data. The creation of a governance system to provide access to 
reference panels and protocols for test validation has been proposed.  
 
D. Regulatory approval  
Regulation is essential to ensure the safety, quality, and effectiveness of diagnostic tests, yet over 
50% of countries do not independently regulate in vitro diagnostics (IVDs) [48]. The regulatory 
landscape for IVDs is highly variable, and regulatory approval mechanisms vary from country to 
country. This makes assay uptake processes slow, costly and not transparent. Regulatory 
harmonization between international and national regulatory agencies, coupled with coordinated 
information sharing among the different interest groups (industry, regulators, researchers, 
laboratories, health systems, and patients) is required. 
 
During outbreak events, emergency use authorizations are generally employed to provide regulatory 
oversight for diagnostics that have not previously been evaluated and yet are urgently needed for 
global response. Both FDA (EUA) and WHO (EUAL) have implemented programs to address the 
evaluation of new diagnostics in an emergency setting. It is important to note that in both cases, 
EUA and/or EUAL approval does not extend approval for use outside of an emergency setting. Once 
an emergency is ended, industry will need to seek approval for regular use of their products in the 
intended settings using either FDA 510(k) or WHO prequalification procedures. The data obtained 
during EUA and/or EUAL approval may be included in the application package for regular approval; 
however, it is likely that additional data will be required for full approval. In these instances, it can 
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be challenging for industry to provide sufficient data, as limited access to well-characterized samples 
can prevent evaluation of the products to the extent required for FDA and WHO approval. As of May 
2017, several ZIKV diagnostic assays have received EUA (15 assays) and/or EUAL (2 assays) [45]; 
however, no single ZIKV assay has been cleared by the FDA to date (Figure 4).  
 
E. Sustainable in-country capacity 
Sustainable in-country capacity is needed for diagnostics to respond in the intermediate and long-
term infectious diseases threats. Higher-cost commercial kits are unlikely to solve this issue at a 
national level in many resource-constrained countries. Therefore, key reagents, protocols, and 
quality control standards (e.g., proficiency panels) must be made available to national reference 
laboratories and other such public-sector entities to ensure wide and sustainable adoption.  
 
Conclusions 
Promising technologies for detection of ZIKV and DENV infections are currently in the pipeline. These 
technologies have the potential to address many of the current challenges of epidemic flaviviral 
diseases. The rate-limiting bottleneck is early access to calibration controls and screening panels as 
well as access to well-characterized samples for development, validation and comparison of the 
performance of different assays. Proficiency testing for both serological and molecular diagnostics 
should be developed for all endemic regions, paired with capacity building. We suggest that an 
international reference laboratory response for flaviviruses is needed, which would include networks 
of in-country laboratories and preparation of protocols for evaluation studies. This could be 
achieved through initiatives such as the Global Dengue and Aedes Transmitted Disease Consortium 
(GDAC), the European Virus Archive, the future EVD-LabNet by the European Centre for Disease 
Prevention and Control, or the Zika research consortia funded by the European Commission[49]. The 
knowledge obtained should be put into the public domain. Researchers and policy-makers alike need 
to ensure mechanisms for greater reagent availability and sharing of standard reagents such as 
reference materials, antigens, monoclonal antibodies, cell lines, control sera, and standardized 
protocols. While this workshop focused on challenges for arbovirus diagnostic development, the key 
outcomes highlighted here translate to all pathogens of epidemic potential.  
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Table 1. Summary table of the challenges and drivers of the pathway to adoption 
Step* Challenges Drivers 
A Market failure due to uncertainty and lack of demand of public 
health emergencies. 
R&D models for diagnostic preparedness - including product development; 
Product development partnerships (PDPs) such as CEPI.dx; 
Other innovative financing models. 
B Target Product Profiles (TPPs)  
- The performance characteristics that are set in the TPP 
are aspirational in nature 
- Often deemed to be too stringent 
Risk and benefit models to set accuracy targets may help inform use of diagnostic tests 
when they do not meet the minimum or ideal characteristics set in the TPP. 
C Lack of clinical samples and resources for clinical validations. Development of international reference standard for assay comparability; 
Improved access to qualified field laboratory networks; 
Access to proficiency panels;  
Development of standardized protocols. 
D Regulatory approval that is region-specific, non-transparent, 
complex, slow and costly. 
Establishment of regulatory networks, common strategies, information-sharing and early-
partnerships. 
E Limited in-country capacity for wide adoption. Mechanisms for appropriate transfer of technology in a more stream-lined fashion; 
Regulation of quality of local laboratories and “in-house” assays for national scale-up and 
sustainable implementation. 
*Steps along the pathway to adoption that require optimization (Figure 4 A-E) 
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